Practical considerations for cangrelor use in patients with acute coronary syndromes.

about

Practical considerations for cangrelor use in patients with acute coronary syndromes.

Item

http://www.wikidata.org/entity/Q53250732

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Practical considerations for cangrelor use in patients with acute coronary syndromes.

@en

Practical considerations for cangrelor use in patients with acute coronary syndromes.

@nl

type

Item

label

Practical considerations for cangrelor use in patients with acute coronary syndromes.

@en

Practical considerations for cangrelor use in patients with acute coronary syndromes.

@nl

prefLabel

Practical considerations for cangrelor use in patients with acute coronary syndromes.

@en

Practical considerations for cangrelor use in patients with acute coronary syndromes.

@nl

P1476

Practical considerations for cangrelor use in patients with acute coronary syndromes.

@en

P2093

Deepak L Bhatt

http://www.w3.org/2001/XMLSchema#string

Sergio Leonardi

http://www.w3.org/2001/XMLSchema#string

P2860

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Effect of platelet inhibition with cangrelor during PCI on ischemic events.

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevati

Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.

Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial.

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).

Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.

Intravenous platelet blockade with cangrelor during PCI.

P304

2048872617707960

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2048872617707960

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28574274

http://www.w3.org/2001/XMLSchema#string